



LKT Laboratories, Inc.

CYT-387

Phone: 888-558-5227
651-644-8424
Fax: 888-558-7329
Email: getinfo@lctlabs.com
Web: lctlabs.com

Product Information

Product ID C9876

CAS No. 1056634-68-4

Chemical Name

Synonym CYT387, CYT11387, Momeletinib

Formula $C_{23}H_{22}N_6O_2$

Formula Wt. 414.46

Melting Point


Purity $\geq 98\%$

Solubility DMSO 74 mg/mL (178.54 mM)
Water Insoluble
Ethanol Insoluble

Store Temp $-20^{\circ}C$

Ship Temp Ambient

Description CYT-387 (momeletinib) is an inhibitor of JAK2 currently under investigation as a potential treatment for myeloproliferative neoplasms; it displays anticancer chemotherapeutic activity. In cellular models of multiple myeloma, momeletinib induces G2/M phase cell cycle arrest. In vivo, this compound decreases tumor burden.



Bulk quantities available upon request

Product ID	Size
C9876	1 mg
C9876	5 mg
C9876	10 mg

References Abubaker K, Luwor RB, Zhu H, et al. Inhibition of the JAK2/STAT3 pathway in ovarian cancer results in the loss of cancer stem cell-like characteristics and a reduced tumor burden. *BMC Cancer*. 2014 May 6;14:317. PMID: 24886434.

Geyer HL, Tibes R, Mesa RA. JAK2 inhibitors and their impact in myeloproliferative neoplasms. *Hematology*. 2012 Apr;17 Suppl 1:S129-32. PMID: 22507800.

Monaghan KA, Khong T, Burns CJ, et al. The novel JAK inhibitor CYT387 suppresses multiple signalling pathways, prevents proliferation and induces apoptosis in phenotypically diverse myeloma cells. *Leukemia*. 2011 Dec;25(12):1891-9. PMID: 21788946.

Caution: This product is intended for laboratory and research use only. It is not for human or drug use.